Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenocarcinoma|Biliary Tract Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07807956 |
M26-326 | P1 |
Not yet recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer|Esophageal Cancer|Biliary Tract Cancer|Colorectal Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Gastrointestinal Cancer|Pancreatic Cancer |
2029-12-01 |
2% |
2026-09-09 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|